These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36344073)

  • 1. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
    Murray TS; Stanley G; Koff JL
    Clin Chest Med; 2022 Dec; 43(4):667-676. PubMed ID: 36344073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
    Murray TS; Stanley G; Koff JL
    Infect Dis Clin North Am; 2024 Mar; 38(1):149-162. PubMed ID: 38280761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
    Conway SP; Brownlee KG; Denton M; Peckham DG
    Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
    Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA
    Ann Am Thorac Soc; 2014 Sep; 11(7):1120-9. PubMed ID: 25102221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis.
    Psoter KJ; De Roos AJ; Wakefield J; Mayer JD; Rosenfeld M
    BMC Infect Dis; 2017 Jun; 17(1):411. PubMed ID: 28599639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
    Rutter WC; Burgess DR; Burgess DS
    Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
    Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
    J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ; Tulu Z; Aris RM; Noone PG
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
    Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL
    Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary infections in patients with cystic fibrosis.
    Rajan S; Saiman L
    Semin Respir Infect; 2002 Mar; 17(1):47-56. PubMed ID: 11891518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
    Mathy V; Grohs P; Compain F
    J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
    Amin R; Waters V
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD009249. PubMed ID: 27415821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review on the use of bacteriophage in treating Staphylococcus aureus and Pseudomonas aeruginosa infections in cystic fibrosis.
    Singh J; Yeoh E; Fitzgerald DA; Selvadurai H
    Paediatr Respir Rev; 2023 Dec; 48():3-9. PubMed ID: 37598024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.
    Waters V
    Curr Pharm Des; 2012; 18(5):696-725. PubMed ID: 22229574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
    Parkins MD; Elborn JS
    J Antimicrob Chemother; 2010 Sep; 65(9):1853-61. PubMed ID: 20605846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
    Amin R; Waters V
    Cochrane Database Syst Rev; 2012 May; (5):CD009249. PubMed ID: 22592739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
    Amin R; Waters V
    Cochrane Database Syst Rev; 2014 Apr; (4):CD009249. PubMed ID: 24696136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.